Drug Trial Radar · NCT07668804
A Study to Evaluate the Safety and Effect of TO-O-1007 Intravitreal Implant in Subjects With Geographic Atrophy
Last checked: Nov 20, 2026Latest source record: Jun 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
31
Planned (sponsor's estimate)
Start
Jun 2, 2026
Primary completion
Aug 31, 2027
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- Theratocular Biotek Co.Industry
- Sponsor type
- Industry
- First posted
- Jun 25, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of TO-O-1007, a biodegradable sustained-release intravitreal implant, for the treatment of Geographic Atrophy (GA) secondary to Age-related Macular Degeneration (AMD). A long-acting intravitreal implant providing sustained delivery of API over 6 months may slow the progression of GA lesions while reducing treatment burden associated with frequent intravitreal injections. TO-O-1007 may offer a convenient treatment option with the potential to preserve retinal structure and visual function while maintaining an acceptable safety profile.
Conditions
- Geographic Atrophy Due to Age-Related Macular Degeneration
Interventions
TO-O-1007 (low-dose)Drug
TO-O-1007 (low-dose): Participants will receive one TO-O-1007 implant administered by intravitreal injection into the study eye.
TO-O-1007 (high-dose)Drug
TO-O-1007 (high-dose): Participants will receive two TO-O-1007 implants administered by intravitreal injection into the study eye.
Sham injectionProcedure
Sham injection: No injection is given. It is a sham injection to keep the participant masked.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Treatment-Emergent Adverse Events (TEAEs)Time frame: Up to 6 months treatment duration
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Retina & Eye Consultants
Hurstville, New South Wales (nsw), Australia · Recruiting
Sydney Retina Clinic & Day Surgery
Sydney, New South Wales (nsw), Australia · Recruiting
Launceston Eye Doctors
Launceston, Tasmania (tas), Australia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.